Mambalgins

mambalgin-1, mambalgin-2, mambalgin-3; pi-Dp1/2/3 (three-finger toxin nomenclature)

Cognitive & neuro

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

1What it is

Mambalgins are peptides from the venom of the black mamba, one of the most feared snakes in Africa. They were described in 2012 by Sylvie Diochot and colleagues in Eric Lingueglia's group at the Institut de Pharmacologie Moléculaire et Cellulaire in Nice, in a paper that attracted attention well beyond pharmacology because of its headline finding: a component of mamba venom produced analgesia in mice as strong as morphine, through a completely different receptor.

Structurally they belong to the three-finger toxin family, the same architectural class as the cobra alpha-neurotoxins and the mamba's own dendrotoxins and fasciculins. Functionally they are nothing like those. Mambalgins do not block nicotinic receptors or acetylcholinesterase and are not themselves lethal components of the venom — the black mamba's lethality comes from dendrotoxins and alpha-neurotoxins, not from mambalgins. Why a snake carries a non-toxic analgesic peptide in its venom is unresolved.

This is a preclinical research compound. Fourteen years after discovery there is still no human data, which is a useful corrective to the frequent description of mambalgins as a "painkiller from snake venom" — they are a laboratory probe and a drug-discovery starting point.

2How it's thought to work

ASIC blockade. Acid-sensing ion channels open when tissue pH falls, as happens in inflammation, ischaemia and tumour growth, and contribute to the pain that accompanies acidosis. Mambalgins inhibit channels containing ASIC1a and ASIC1b subunits, and have distinct effects on central (ASIC1a, spinal) and peripheral (ASIC1b, sensory neuron) populations.

Gating modifier, not pore blocker. Structural and functional work indicates mambalgins bind the extracellular thumb domain and shift the channel's pH dependence of activation, rather than plugging the pore. This matters because it suggests a drugable allosteric site.

Opioid-independent analgesia. Mambalgin analgesia in mice is not blocked by naloxone, is not accompanied by respiratory depression, and in the published experiments did not produce the rapid tolerance seen with morphine. These three properties are the entire basis of therapeutic interest — an analgesic mechanism outside the opioid system.

Interaction with endogenous opioids. Some of the central analgesic effect has been reported to involve ASIC1a-dependent modulation of endogenous opioid signalling, so the separation from opioid pharmacology may be less absolute than first described.

Black mamba peptides that block acid-sensing ion channels. In mice they relieve pain as strongly as morphine without respiratory depression; no human studies.Schematic — not to scale

3What the research shows

Acute and inflammatory pain in rodents

The founding study reported that mambalgin-1 and -2 given intrathecally or intracerebroventricularly produced strong, naloxone-resistant analgesia in mice in thermal and inflammatory pain models, with potency comparable to morphine in the assays used, and that local injection was effective against inflammatory pain through a peripheral ASIC1b mechanism (Diochot 2012, Nature). [1]

Neuropathic pain in rodents

Subsequent rodent work has reported effects in neuropathic and chemotherapy-induced pain models. The body of evidence remains small and almost entirely from the originating group and close collaborators.

Mechanism and structure

Binding-site mapping, structural determination and mutagenesis have defined how mambalgins engage the ASIC thumb domain and why they discriminate between subunits (Diochot 2016, PNAS; Mourier 2016, J Biol Chem; Salinas 2014, J Physiol). This is the most solid part of the literature, and the reason mambalgins are now a standard pharmacological tool for ASIC work. [2][3][4]

Not gradednone

Human data

There are no clinical trials, no Phase 1 safety data and no human pharmacokinetics. Statements that mambalgins are a painkiller "in development" should be read as drug discovery interest, not a clinical programme. A note on the literature's thinness. For a finding published in Nature and widely covered in the press, the follow-up literature is modest and heavily concentrated in one laboratory. Independent replication of the central analgesic effect is limited. That is a reason for caution about the size of the effect, not a reason to dismiss the mechanism, which is well supported structurally.

4Reported side effects and interactions

Literature-reported

Literature. no human safety data exists. In the rodent studies the peptides were reported to lack the respiratory depression, sedation and rapid tolerance that characterise opioids. ASIC1a has roles in fear conditioning, learning and ischaemic neuronal death, so central blockade would be expected to have central consequences; these have not been systematically characterised.

Literature (envenomation). black mamba bite is a medical emergency — rapid descending flaccid paralysis and respiratory failure from dendrotoxins and alpha-neurotoxins, requiring antivenom and ventilatory support. This has nothing to do with mambalgin pharmacology but is the only route by which a human has ever been exposed to these peptides.

Community-reported

Community use: essentially none documented. Self-administration would be both pointless and dangerous — the analgesic effects were produced by injection into the spinal canal or brain ventricles of rodents, routes with no self-administration equivalent, and no systemic dose has been shown to do anything.

Theoretical. immunogenicity of a 57-amino-acid snake peptide on repeat dosing; the central route used in all the efficacy work (intrathecal or intracerebroventricular) is itself a major clinical limitation; ASIC1a blockade in the brain could plausibly affect fear and memory processing.

Interactions. none established.

Markers researchers commonly monitor

No compound-specific markers are established and no human administration occurs, so there is nothing to monitor clinically. In the preclinical literature the measures are behavioural and electrophysiological: No human laboratory markers apply.

Marker	Why it's watched
Nociceptive behavioural assays (thermal withdrawal latency, mechanical thresholds, formalin and complete Freund's adjuvant models)	the actual efficacy readouts.
Naloxone challenge	the experiment that establishes opioid independence and the basis of the mechanistic claim.
ASIC currents in patch-clamp recordings	the direct pharmacological measure of target engagement.
Respiratory rate and arterial blood gases in rodents	the comparison against opioids that gives the mechanism its appeal.

Free for everyone. Safety information is never behind a paywall.

5Research context and safety notes

Mambalgins are laboratory reagents used to interrogate ASIC function. The relevant constraints: - Route. Every reported analgesic effect required intrathecal, intracerebroventricular or direct local injection. Peptides of this size do not cross the blood–brain barrier, so the central effects cannot be reproduced systemically. This is the central translational obstacle, not an incidental detail. - Potency scale and unknown systemic toxicology. Effects in rodents were produced by nanomole quantities delivered centrally. There is no toxicology package, no human safety data and no characterised therapeutic index in any species. - Source. Research material is synthetic or recombinant. Crude black mamba venom is a lethal biological hazard handled only in licensed facilities. No preparation, solvent, concentration or storage guidance is given here. There is no established human use for which such guidance would be meaningful.

6Commonly studied alongside

Amiloride and PcTx1 (psalmotoxin-1, another spider-venom ASIC1a blocker) as comparator ASIC pharmacology; Hi1a (#199), which blocks the same channel family for a different indication; conotoxins (#194) and ziconotide (#134) as the venom-peptide analgesics that did and did not reach the clinic.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	Not FDA-approved; not in clinical development. Research chemical only
European Union	Not authorised
United Kingdom	Not licensed
Australia	Not approved
South Africa	Not registered. (Noted because the source species is native to the region; venom collection and export are subject to wildlife and biodiversity controls †)
Sport	Not listed by WADA; S0 would apply in principle to any non-approved substance administered to an athlete

8Open questions

Can ASIC1 blockade be achieved by a molecule that reaches the target after systemic or oral administration? This is the question the whole area turns on.
How large is the analgesic effect outside the originating laboratory?
What are the consequences of central ASIC1a blockade for fear, memory and ischaemic tolerance?
What is the biological function of a non-toxic analgesic peptide in a venom?

9References

1Diochot S et al. (2012). Black mamba venom peptides target acid-sensing ion channels to abolish pain. Nature. PubMed · DOI
2Diochot S et al. (2016). Analgesic effects of mambalgin peptide inhibitors of acid-sensing ion channels in inflammatory and neuropathic pain. Pain. PubMed · DOI
3Mourier G et al. (2016). Mambalgin-1 pain-relieving peptide, stepwise solid-phase synthesis, crystal structure, and functional domain for acid-sensing ion channel 1a inhibition. J Biol Chem. PubMed · DOI
4Salinas M et al. (2014). Binding site and inhibitory mechanism of the mambalgin-2 pain-relieving peptide on acid-sensing ion channel 1a. J Biol Chem. PubMed · DOI
5Baron A, Lingueglia E (2015). Pharmacology of acid-sensing ion channels — physiological and therapeutical perspectives. Neuropharmacology. PubMed · DOI

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

31 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.